NEW YORK (GenomeWeb News) – Arrayit Diagnostics said today that it has exclusively licensed ovarian cancer biomarker intellectual property from Wayne State University.

Under the agreement, Houston-based Arrayit Diagnostics, a majority-owned subsidiary of Sunnyvale, Calif.-based Arrayit Corporation, gains exclusive worldwide rights to develop and commercialize a microarray-based diagnostic test using the biomarkers, which were developed by WSU researchers Michael Tainsky, Sorin Draghici, and Madhumita Chatterjee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.